Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Doctors want to know if giving emapalumab as upfront pre-treatment works well for people with severe acquired aplastic anemia (sAA). This medication is given after diagnosis, but before standard sAA treatment. In people with sAA, stem cells are destroyed and the body cannot make new blood cells.
Researchers are seeking the best dose of mRNA-4203 to give with a cellular therapy in people with melanoma or sarcoma. The cellular therapy is called IMA203 and is custom-made from each patient's white blood cells.
Metaiodobenzylguanidine (MIBG) is a substance taken up specifically by neuroblastoma, pheochromocytoma, or paraganglioma tumor cells. MIBG can be combined with radioactive iodine (<sup>131</sup>I) in the laboratory to form the radioactive compound <sup>131</sup>I-MIBG. The <sup>131</sup>I-MIBG compound concentrates more in cancer cells than in normal cells. It may therefore deliver more radiation directly to cancer cells while sparing normal organs.
Researchers want to find the best schedule for giving a new vaccine to people with neuroblastoma. The people in this study have neuroblastoma that is in remission (no signs of cancer). In addition, their cancers have a strong chance of coming back (high risk). The vaccine is given with a naturally occurring substance called beta-glucan.
Researchers want to see if adding IMNN-001 to standard treatment works well against advanced gynecologic cancers. The people in this study have newly diagnosed ovarian, fallopian tube, or primary peritoneal cancers.
Researchers in this study are assessing the drug ACR-368 alone and in combination with increasing doses of low-dose gemcitabine in people with ovarian, endometrial, or urothelial (bladder) cancer that has come back despite prior treatment. ACR-368 works by stopping cancer cells from repairing damage to themselves and their DNA (genes). Gemcitabine damages the DNA inside cancer cells and prevents the cells from multiplying.
In this study, researchers are comparing a combination of two new drugs with standard treatment for ovarian cancer. The two drugs are avutometinib and defactinib. The people in this study have low-grade serous ovarian cancer that came back after treatment.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the most effective treatments for prostate cancers that have spread to other organs (metastasized). The benefits of hormone treatments do not last, however. Over time, many prostate cancers continue to grow despite hormonal therapies; these are called "castration-resistant prostate cancers" (CRPC).
The purpose of this study is to find the highest dose of the investigational drug PC14586 that can be given in patients with solid tumors that came back or continue to grow despite prior therapy and contain a mutation in the TP53 gene. The p53 protein produced by this gene normally tells cells when to stop dividing, but when TP53 is altered (mutated), cancer may result.
